News
Some on Wall Street who counted on President Donald Trump to revive dealmaking are now biting their tongues.
Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback